Lilly’s oral GLP‑1 hits U.S.

Weight-loss drugs work by copying gut signals that normally tell your brain “you’ve eaten enough,” and the glucagon-like peptide-1 signal is the one behind medicines like Wegovy and Zepbound. Until now, the strongest sellers in that class have mostly been weekly shots, which turned obesity treatment into something that often started with a needle. (nejm.org) Lilly’s new pill is called Foundayo, and the drug inside it is orforglipron. The U.S. Food and Drug Administration approved it on April 1, 2026, for adults with obesity or for adults who are overweight and also have at least one weight-related medical problem. (fda.gov) The news this week is not the approval but the launch. Lilly said on April 9, 2026, that Foundayo is now available in the United States through LillyDirect, telehealth providers, and retail pharmacies nationwide. (prnewswire.com) What makes this pill different is the routine. Lilly says Foundayo can be taken at any time of day and does not come with food or water restrictions, which is a simpler setup than Novo Nordisk’s diabetes pill Rybelsus, whose label requires taking it on an empty stomach with no more than 4 ounces of water and then waiting 30 minutes before eating, drinking, or taking other oral medicines. (prnewswire.com) (novomedlink.com) The reason Lilly could make a simpler pill is chemistry. Orforglipron is a small-molecule drug, which means it is built more like a conventional tablet than the fragile peptide drugs that usually need an injection or special handling to survive the stomach. (drugs.com) The main evidence came from a 72-week study called ATTAIN-1. In the New England Journal of Medicine, people taking 36 milligrams of orforglipron lost 11.2% of their body weight on average, versus 2.1% with placebo, and Lilly’s launch materials translate the top-dose result to about 27 pounds on average. (nejm.org) (prnewswire.com) The tradeoff looked familiar to anyone who has followed this drug class. The most common side effects in the trial were stomach-related problems like nausea, vomiting, and diarrhea, and treatment discontinuation ranged from 5.3% to 10.3% on orforglipron versus 2.7% on placebo. (nejm.org) The label also carries the boxed warning seen on other glucagon-like peptide-1 drugs about thyroid C-cell tumors. The prescribing information says Foundayo should not be used in patients with a personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2. (drugs.com) Lilly is trying to use price to widen the market fast. The company says the drug starts at $25 a month for people with commercial coverage and $149 a month for self-pay through LillyDirect, which is far below the list prices that made injectable obesity drugs a reimbursement fight. (prnewswire.com) This also gives Lilly a second obesity product in the United States next to Zepbound, its injectable drug based on tirzepatide. The bigger bet is that a daily pill could pull in people who never wanted a weekly shot, which would turn the weight-loss market from a specialty pharmacy business into something closer to a standard chronic-disease prescription. (prnewswire.com)